Genmab A/S (GMAB) Q3 2022 Earnings Call Transcript

For the period ending September 30, 2022

November 9, 2022 12:00 p.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Hello, and welcome to the Genmab Q3 2022 Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans or expects.

Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless it is required by law.

Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.

Jan van de Winkel

Hello, and welcome to the Genmab conference call to discuss our financial results for the first nine months of 2022. With me today to present these results is our CFO, Anthony Pagano. And then for the Q&A, we will be joined by our Chief Medical Officer, Tahi Ahmadi.

Let’s move to Slide 2. As already said, we will be making forward-looking statements, so please keep that in mind as we go through this call.

Let’s move to Slide 3. Genmab has a science and cost and innovation-based culture and collaborations and partnerships have always been part of our DNA. During today’s presentation, we will reference some of the products being developed under these strategic collaborations, and this slide acknowledges those relationships.

Let’s move to Slide 4. When we presented this slide during our first quarter earnings call, we said that we have never been in a better position to achieve our ambitious vision of transforming cancer treatments. We made that assertion on the basis of our consistent track record, our world-class team and our strong financial foundation. Since Q1, we have strengthened our position.

In the first nine months of the year, we increased the number of cumulative INDs, the number of approved medicines powered by Genmab’s innovation and the number of clinical-stage products in our own pipeline. We’ve also grown and strengthened the team, and our financial foundation is even more robust. So we continue to feel really well-positioned for growth moving forward. Excitingly, we have the potential to further increase the number of approved products in the coming year. You can see that on the next slide, which covers our recent key updates.